Eli Lilly Q2 2024 Adj. EPS $3.92 Beats $2.70 Estimate, Sales $11.303B Beat $9.949B Estimate
Portfolio Pulse from Benzinga Newsdesk
Eli Lilly reported its Q2 2024 adjusted EPS of $3.92, significantly beating the estimate of $2.70. The company's sales also surpassed expectations, coming in at $11.303 billion compared to the estimated $9.949 billion.
August 08, 2024 | 10:46 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Eli Lilly's Q2 2024 adjusted EPS of $3.92 and sales of $11.303 billion both significantly beat estimates, indicating strong financial performance.
Eli Lilly's strong Q2 2024 financial results, with both EPS and sales significantly beating estimates, are likely to positively impact the stock price in the short term. This demonstrates robust business performance and investor confidence.
CONFIDENCE 100
IMPORTANCE 90
RELEVANCE 100